These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

356 related items for PubMed ID: 22382781

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Feasibility and safety of extended adjuvant temozolomide beyond six cycles for patients with glioblastoma.
    Hsieh SY, Chan DT, Kam MK, Loong HH, Tsang WK, Poon DM, Ng SC, Poon WS.
    Hong Kong Med J; 2017 Dec; 23(6):594-8. PubMed ID: 28798282
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Prolonged Temozolomide Maintenance Therapy in Newly Diagnosed Glioblastoma.
    Skardelly M, Dangel E, Gohde J, Noell S, Behling F, Lepski G, Borchers C, Koch M, Schittenhelm J, Bisdas S, Naumann A, Paulsen F, Zips D, von Hehn U, Ritz R, Tatagiba MS, Tabatabai G.
    Oncologist; 2017 May; 22(5):570-575. PubMed ID: 28360216
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.
    Lanzetta G, Campanella C, Rozzi A, Nappa M, Costa A, Fedele F, Innocenzi G, Gagliardi FM, Salvati M, Minniti G, Frati A, Frati L, Vecchione A.
    Anticancer Res; 2003 May; 23(6D):5159-64. PubMed ID: 14981983
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Radiochemotherapy with temozolomide for patients with glioblastoma. Prognostic factors and long-term outcome of unselected patients from a single institution.
    Gerstein J, Franz K, Steinbach JP, Seifert V, Rödel C, Weiss C.
    Strahlenther Onkol; 2011 Nov; 187(11):722-8. PubMed ID: 22037649
    [Abstract] [Full Text] [Related]

  • 14. Hypofractionated radiotherapy with or without concurrent temozolomide in elderly patients with glioblastoma multiforme: a review of ten-year single institutional experience.
    Cao JQ, Fisher BJ, Bauman GS, Megyesi JF, Watling CJ, Macdonald DR.
    J Neurooncol; 2012 Apr; 107(2):395-405. PubMed ID: 22105851
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Outcome of newly diagnosed glioblastoma patients treated by radiotherapy plus concomitant and adjuvant temozolomide: a long-term analysis.
    Erpolat OP, Akmansu M, Goksel F, Bora H, Yaman E, Büyükberber S.
    Tumori; 2009 Apr; 95(2):191-7. PubMed ID: 19579865
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Patterns of care and survival for patients with glioblastoma multiforme diagnosed during 2006.
    Yabroff KR, Harlan L, Zeruto C, Abrams J, Mann B.
    Neuro Oncol; 2012 Mar; 14(3):351-9. PubMed ID: 22241797
    [Abstract] [Full Text] [Related]

  • 20. Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.
    Ishikawa E, Muragaki Y, Yamamoto T, Maruyama T, Tsuboi K, Ikuta S, Hashimoto K, Uemae Y, Ishihara T, Matsuda M, Matsutani M, Karasawa K, Nakazato Y, Abe T, Ohno T, Matsumura A.
    J Neurosurg; 2014 Sep; 121(3):543-53. PubMed ID: 24995786
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.